Valuation: BioNTech SE

Market Cap 20.18B 23.3B 18.91B 17.25B 32.43B 2,222B 32.93B 222B 86.95B 1,113B 87.47B 85.57B 3,710B P/E 2026 *
-14.6x
P/E 2027 * -15.2x
Enterprise Value 9.41B 10.86B 8.81B 8.04B 15.11B 1,035B 15.34B 104B 40.51B 518B 40.76B 39.87B 1,729B EV / Sales 2026 *
5.14x
EV / Sales 2027 * 5.76x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.06%
1 week+0.61%
Current month+2.38%
1 month+1.37%
3 months-0.98%
6 months-12.31%
Current year-2.58%
1 week 91.57
Extreme 91.57
94.27
1 month 88.2
Extreme 88.2
94.41
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
388
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-0.06%+0.61%-16.45%-13.26% 23.3B
-0.73%+7.82%+73.81%+102.34% 70.1B
-0.37%+0.58%+37.65%+65.87% 54.93B
-0.22%+33.59%+8.43%+489.75% 28.89B
+0.04%+10.49%+48.44%+7.45% 23.9B
-1.37%+7.87%+251.71%+464.53% 18.41B
-0.47%+7.88%+40.87%-20.12% 18.77B
-0.57%+3.44%+25.60%+619.86% 16.1B
-1.85%-11.15%+32.75%+134.11% 12.48B
-2.23%+0.39%+390.17%+202.43% 12.32B
Average -0.79%+7.58%+89.30%+205.30% 27.92B
Weighted average by Cap. -0.62%+9.03%+69.09%+168.80%

Financials

2026 *2027 *
Net sales 1.83B 2.11B 1.71B 1.56B 2.94B 201B 2.99B 20.17B 7.88B 101B 7.93B 7.76B 336B 1.86B 2.15B 1.75B 1.59B 3B 205B 3.04B 20.54B 8.03B 103B 8.08B 7.9B 343B
Net income -1.34B -1.55B -1.26B -1.15B -2.15B -148B -2.19B -14.77B -5.77B -73.9B -5.81B -5.68B -246B -1.34B -1.55B -1.25B -1.14B -2.15B -147B -2.18B -14.76B -5.77B -73.82B -5.8B -5.68B -246B
Net Debt -10.78B -12.44B -10.1B -9.21B -17.32B -1,187B -17.58B -119B -46.43B -594B -46.71B -45.7B -1,981B -9.44B -10.9B -8.85B -8.07B -15.17B -1,039B -15.4B -104B -40.67B -520B -40.92B -40.03B -1,735B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
14/08/26 USD 92.19 -0.59% 63,876
12/08/26 USD 92.74 -0.06% 476,504
11/08/26 USD 92.80 0.00% 705,979
10/08/26 USD 92.80 -0.93% 731,127
07/08/26 USD 93.67 +2.72% 1,427,941
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.35EUR
Average target price
104.26EUR
Spread / Average Target
+29.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock